看见一个 Expert Review of Anticancer Therapy。你们前面用依维莫斯,血、肝肾功能还好。下一步是否考虑索拉非尼+依维莫斯。供你参考。. }- \% f( Y' A( s# [' \# P' `6 e: I* s
4 D0 ]- U# P+ x
. U* [6 b$ x2 x3 N0 X
Currently available feasibility data for possible combination strategies. # f- {5 L8 `2 k5 {; F
————————————————————————————————$ Y7 S0 g H/ C5 [/ i. ~% J4 \
Combination Feasibility according to preliminary data ) l0 ^: l( e5 @: j% u( n
——————————————————————————————————8 n! o# e; y5 s7 ?% C% P
Bevacizumab + sorafenib Yes, reduced dose
; c1 b% n) k5 Y" `' Y( S" e% @Bevacizumab + sunitinib† No " t0 i# w& t2 T! L9 a+ r5 V
Bevacizumab + temsirolimus Yes
( i* N2 h. l* f2 e* dBevacizumab + everolimus Yes . S+ O& }; s- F! z
Sorafenib + sunitinib ? " n) d+ I0 C" v" X7 v% ]7 Z2 D
Sorafenib + temsirolimus Yes, reduced dose
4 N. _/ T& k S; S5 r- D! O" }) C3 X. F% iSorafenib + everolimus Yes, reduced dose ; t. o* O- _. \& Y3 [! k
Sunitinib + temsirolimus† No
$ n; l" O( ^1 Q5 V; I. cSunitinib + everolimus ?
b( ^) D5 U; u3 j) p. ^. CTemsirolimus + everolimus ? ! L1 `* \, ^2 t/ Y
————————————————————
6 e+ y6 U: P, O7 M m0 N! B) f†Led to US FDA warning.
, S! J: t) F# D1 z' x* Y?: As yet unattempted combination.& a1 n( G- ]$ ~( v# Z& D
|